Research Papers: Gynecological CancersAspirin and risk of endometrial cancer: a case–control study from ItalyBosetti, Cristinaa; Bravi, Francescaa b; Talamini, Renatoc; Montella, Mauriziod; Negri, Evaa; La Vecchia, Carloa bAuthor Information aIstituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa bIstituto di Statistica Medica e Biometria G.A. Maccacaro, Università degli Studi di Milano, Via Venezian, Milan cS.O.C. di Epidemiologia e Biostatistica, Centro di Riferimento Oncologico (IRCCS), Via Gallino, Aviano (PN) dS.S.D. Epidemiologia, Istituto Nazionale Tumori Fondazione G. Pascale, Via Mariano Semmola, Napoli, Italy Correspondence to Professor Carlo La Vecchia, MD, Istituto di Ricerche Farmacologiche Mario Negri, Via G. La Masa 19 – 20156 Milan, Italy Tel: +39 239014527; fax: +39 233200231; e-mail: [email protected] Received 19 January 2010 Accepted 10 March 2010 European Journal of Cancer Prevention: September 2010 - Volume 19 - Issue 5 - p 401-403 doi: 10.1097/CEJ.0b013e32833b4871 Buy Metrics Abstract Data on the role of aspirin on endometrial cancer risk are scanty. Here we provide additional information on the issue, using data from a multicentric Italian case–control study. The study was conducted between 1992 and 2006 in three Italian areas, on 442 cases with histologically confirmed endometrial cancer and 676 control women admitted to the same hospitals as cases for a wide spectrum of acute, non-neoplastic, non-gynaecological, non-hormone-related conditions, providing information on aspirin use. Odds ratios (OR) of endometrial cancer and corresponding 95% confidence intervals were calculated using multiple logistic regression models, including terms for sociodemographic characteristics, body mass index and hormonal and reproductive factors. Regular aspirin use was reported by 28 (6.3%) cases and 46 (6.8%) controls, corresponding to a multivariate OR of 0.65 (95% confidence interval 0.37–1.11). There was no consistent pattern of risk with duration of use, nor with age at first use, time since first use or time since last use. Further, there was no difference in risk estimates across strata of body mass index. This study – the first one from a population outside North America – adds relevant information on the absence of a consistent association between aspirin use and endometrial cancer risk, even in high-risk overweight and obese women. © 2010 Lippincott Williams & Wilkins, Inc.